StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) shareholders

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)

Close on Nov 17, 2026Market cap $43.60MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
58.9%
3M of 6M shares
Institutional holders
26
10 new, 7 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
1 buys · 2 sales
Net bought $38.28K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Gilead Sciences, Inc.14,517,67819.90%13G (passive) amendmentDec 31, 2025
Gilead Sciences Inc9,105,45119.90%13G (passive) amendmentDec 18, 2024
Fhmlsp, L.P.
Joint filing with Frazier Life Sciences Public Fund, L.P. (9.90%), Fhmlsp, L.L.C. (9.90%)
8,141,0179.90%13G (passive) amendmentJun 30, 2025
Point72 Asset Management, L.P.
Joint filing with Point72 Capital Advisors, Inc. (9.90%), Steven A. Cohen (9.90%)
8,000,0009.90%13G (passive) amendmentSep 30, 2025
Yekaterina Chudnovsky
Joint filing with Gkcc, LLC (15.90%)
7,000,00015.90%13G (passive)Jun 7, 2024
James N. Topper
Joint filing with Patrick J. Heron (9.90%), Albert Cha (8.10%) and 4 more
5,747,1939.90%13G (passive)Jun 5, 2025
Coastlands Capital LLC
Joint filing with Coastlands Capital LP (9.99%), Coastlands Capital Partners LP (9.99%) and 2 more
5,346,0699.99%13G (passive)Dec 4, 2025
Frazier Life Sciences Public Fund, L.P.
Joint filing with Fhmlsp, L.P. (6.70%), Fhmlsp, L.L.C. (6.70%)
4,676,4726.70%13G (passive) amendmentDec 31, 2025
AbbVie Inc.4,347,8269.00%13G (passive)Feb 11, 2025
StemPoint Capital LP
Joint filing with StemPoint Capital Management GP LLC (7.20%), Michelle Ross (7.20%)
4,000,0007.20%13G (passive)Sep 30, 2025
Alex Silverstein
Joint filing with Sirenia Capital Management LP (9.90%)
1,142,8629.90%13G (passive)Mar 31, 2026
BCLS II Equity Opportunities, LP664,0219.99%13G (passive) amendmentMar 31, 2026
Orbimed Advisors LLC
Joint filing with OrbiMed Capital GP X LLC (7.49%)
642,0009.99%13G (passive)Mar 31, 2026
Michelle Ross
Joint filing with StemPoint Capital LP (9.50%), StemPoint Capital Management GP LLC (9.50%)
628,8669.50%13G (passive) amendmentJun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of XLOValueChange% of portfolio
Bain Capital Life Sciences Investors, LLC664,02111.48%$6.36M–0.38%
Gilead Sciences, Inc.650,38911.25%$6.23M–0.38%
Orbimed Advisors LLC592,30010.24%$5.67MNew0.11%
Frazier Life Sciences Management, L.P.422,5057.31%$4.05M–0.09%
Stonepine Capital Management, LLC225,9943.91%$2.17M+161,8321.22%
Vanguard Capital Management LLC178,5173.09%$1.71M+54,8570.00%
Sio Capital Management, LLC152,4642.64%$1.46M–0.24%
Adage Capital Partners Gp, L.L.C.111,5411.93%$1.07MNew0.00%
Merck & Co., Inc.105,9821.83%$1.02M–0.19%
Renaissance Technologies LLC64,1531.11%$614.59K+14,5870.00%
Morgan Stanley56,9540.98%$545.62K−5390.00%
Geode Capital Management, LLC39,0550.68%$374.17K+1,8580.00%
Citadel Advisors LLC25,9500.45%$248.60KNew0.00%
Vanguard Fiduciary Trust Co22,5940.39%$216.45K−5,8810.00%
Bridgeway Capital Management, LLC17,5440.30%$168.07KNew0.00%
Two Sigma Investments, LP14,5440.25%$139.33KNew0.00%
Velan Capital Investment Management LP14,2850.25%$136.85K–0.08%
Gsa Capital Partners Llp13,5900.24%$130.00K−3,3560.01%
State Street Corp13,3110.23%$127.52K–0.00%
Prelude Capital Management, LLC11,6000.20%$111.13KNew0.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026263M58.9%10 / 44 / 71M0M
Q1 2026243M45.3%7 / 78 / 191M1M
Q4 2025373M49.1%11 / 45 / 91M0M
Q3 2025362M27.2%4 / 64 / 30M0M
Q2 2025352M29.4%5 / 411 / 50M0M
Q1 2025352M27.8%6 / 87 / 60M0M
Q4 2024352M31.9%9 / 65 / 51M0M
Q3 2024331M19.7%6 / 84 / 40M0M
Q2 2024321M17.9%7 / 96 / 60M0M
Q1 2024311M16.0%6 / 45 / 80M0M
Q4 2023341M20.5%6 / 84 / 30M0M
Q3 2023311M19.6%2 / 57 / 30M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

10 funds held XLO in Q2 2026, 78% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of XLOValue% of fundAs of
Vanguard Total Stock Market Index Fund142,4402.46%$1.36M0.00%Jun 30, 2026
Vanguard Extended Market Index Fund35,6060.62%$341.11K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund19,8240.34%$167.71K0.00%May 31, 2026
Ultra-Small Company Fund17,5440.30%$168.07K0.17%Jun 30, 2026
iShares Micro-Cap ETF8,2190.14%$78.74K0.01%Jun 30, 2026
Fidelity Series Total Market Index Fund7,4760.13%$63.25K0.00%May 31, 2026
Fidelity Total Market Index Fund4,5140.08%$38.19K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund2,7680.05%$23.42K0.00%May 31, 2026
U.S. Vector Equity Portfolio1,5070.03%$13.73K0.00%Jul 31, 2026
Dimensional US Core Equity 1 ETF1,1160.02%$10.17K0.00%Jul 31, 2026
1290 VT Micro Cap Portfolio5380.01%$5.15K0.00%Jun 30, 2026
Vanguard Balanced Index Fund4710.01%$4.51K0.00%Jun 30, 2026
Dimensional U.S. Core Equity 2 ETF2540.00%$2.31K0.00%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Rene RussoPRESIDENT AND CEO, Director325,4225.63%Jan 5, 2026
Yariv HouvrasCHIEF MEDICAL OFFICER––Oct 2, 2026
Christopher James FrankenfieldChief Financial Officer24,7660.43%Jan 5, 2026
Kevin M. BrennanSVP, FINANCE AND ACCOUNTING6,3710.11%Jan 5, 2026
Katarina LuptakovaCHIEF MEDICAL OFFICER33,2500.58%Jan 5, 2026
Daniel J. CurranDirector––Jun 12, 2026
Yuan XuDirector––Jun 12, 2026
Robert W. RossDirector––Jun 12, 2026
James Samuel ShannonDirector10,0000.17%Jun 12, 2026
Aoife BrennanDirector––Jun 12, 2026
Sara BonsteinDirector––Jun 12, 2026
Akintunde Olatokumbo BelloDirector––Jun 12, 2026
Cheryl R. BlanchardDirector––Apr 16, 2026
Paul J. ClancyDirector––Jun 12, 2025
Christina RossiDirector––Jun 12, 2025
Gilead Sciences, Inc.10% owner9,105,451157.47%Feb 17, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
James Samuel Shannon
Director
Mar 26, 2026Buy+5,000$8.79$43.95K10,000
Kevin M. Brennan
SVP, FINANCE AND ACCOUNTING
Jan 2, 2026Sale(10b5-1 plan)−1,826$0.64$1.17K6,371
Christopher James Frankenfield
Chief Financial Officer
Jan 2, 2026Sale(10b5-1 plan)−7,030$0.64$4.50K24,766
Katarina Luptakova
CHIEF MEDICAL OFFICER
Jan 1, 2026Option exercise+16,625––33,250
Rene Russo
PRESIDENT AND CEO, Director
Jan 1, 2026Option exercise+44,250––325,422
Kevin M. Brennan
SVP, FINANCE AND ACCOUNTING
Jan 1, 2026Option exercise+5,000––8,197
Christopher James Frankenfield
Chief Financial Officer
Jan 1, 2026Option exercise+19,375––31,796
James Samuel Shannon
Director
Jun 17, 2025Buy+25,000$0.69$17.25K70,000
Rene Russo
PRESIDENT AND CEO, Director
Jun 16, 2025Buy+36,289$0.68$24.68K281,172
James Samuel Shannon
Director
Jun 16, 2025Buy+45,000$0.69$31.05K45,000
Kevin M. Brennan
SVP, FINANCE AND ACCOUNTING
Jan 2, 2025Sale(10b5-1 plan)−1,803$0.98$1.77K3,197
Christopher James Frankenfield
Chief Financial Officer
Jan 2, 2025Sale(10b5-1 plan)−6,954$0.98$6.81K12,421
Kevin M. Brennan
SVP, FINANCE AND ACCOUNTING
Jan 1, 2025Option exercise+5,000––5,000
Rene Russo
PRESIDENT AND CEO, Director
Jan 1, 2025Option exercise+44,250––244,883
Katarina Luptakova
CHIEF MEDICAL OFFICER
Jan 1, 2025Option exercise+16,625––16,625
Christopher James Frankenfield
Chief Financial Officer
Jan 1, 2025Option exercise+19,375––19,375
Gilead Sciences, Inc.
10% owner
Dec 18, 2024Buy+1,759,978$1.04$1.83M9,105,451
Gilead Sciences, Inc.
10% owner
Apr 2, 2024Buy+485,250$0.76$368.79K7,345,473
Atlas Venture Fund XI, L.P.
10% owner
Feb 8, 2024Sale−733$0.64$4692,019,563
Atlas Venture Fund XI, L.P.
10% owner
Feb 8, 2024Sale−267$0.64$171734,546
Atlas Venture Associates Opportunity I, L.P.
10% owner
Jan 12, 2024Sale−1,540$0.83$1.28K2,020,296
Atlas Venture Associates Opportunity I, L.P.
10% owner
Jan 12, 2024Sale−560$0.83$465734,813
Atlas Venture Associates Opportunity I, L.P.
10% owner
Jan 11, 2024Sale−569$0.87$495735,373
Atlas Venture Associates Opportunity I, L.P.
10% owner
Jan 11, 2024Sale−1,566$0.87$1.36K2,021,836
BCIP Life Sciences Associates, LP
10% owner
Dec 10, 2021Buy+21,812$9.56$208.52K2,802,225
BCIP Life Sciences Associates, LP
10% owner
Dec 10, 2021Buy+3,188$10.24$32.65K2,805,413
BCIP Life Sciences Associates, LP
10% owner
Dec 9, 2021Buy+4,011$9.84$39.47K2,780,413
BCIP Life Sciences Associates, LP
10% owner
Dec 8, 2021Buy+13,458$9.62$129.47K2,776,402
Impact Medicine Fund LP SV7
10% owner
Oct 26, 2021Buy+312,500$16.00$5.00M1,613,632
Impact Medicine Fund LP SV7
10% owner
Oct 26, 2021Buy+312,500$16.00$5.00M1,613,632
Impact Medicine Fund LP SV7
10% owner
Oct 26, 2021Conversion+302,588––1,301,132
Impact Medicine Fund LP SV7
10% owner
Oct 26, 2021Conversion+302,588––1,301,132
Impact Medicine Fund LP SV7
10% owner
Oct 26, 2021Conversion+998,544––998,544
Impact Medicine Fund LP SV7
10% owner
Oct 26, 2021Conversion+998,544––998,544
(Imf) Gp Llp Sv7
10% owner
Oct 26, 2021Conversion+302,588––1,301,132
(Imf) Gp Llp Sv7
10% owner
Oct 26, 2021Conversion+302,588––1,301,132
(Imf) Gp Llp Sv7
10% owner
Oct 26, 2021Conversion+998,544––998,544
(Imf) Gp Llp Sv7
10% owner
Oct 26, 2021Conversion+998,544––998,544
Mgmt L.P. Deerfield
10% owner
Oct 26, 2021Conversion+756,472––756,472
Mgmt L.P. Deerfield
10% owner
Oct 26, 2021Conversion+756,472––756,472
Mgmt L.P. Deerfield
10% owner
Oct 26, 2021Buy+387,500$16.00$6.20M1,143,972
Mgmt L.P. Deerfield
10% owner
Oct 26, 2021Buy+387,500$16.00$6.20M1,143,972
Llc Fmr
–
Oct 26, 2021Conversion+789,473––815,788
Llc Fmr
–
Oct 26, 2021Conversion+372,215––372,215
Llc Fmr
–
Oct 26, 2021Conversion+28,703––1,530,990
Llc Fmr
–
Oct 26, 2021Conversion+686,499––1,502,287
Llc Fmr
–
Oct 26, 2021Conversion+4,465––4,465
Ltd FIL
–
Oct 26, 2021Conversion+218,705––218,705
Takeda Ventures, Inc.
10% owner
Oct 26, 2021Conversion+1,475,121––1,475,121
City Capital Llc Bay
10% owner
Oct 26, 2021Buy+312,500$16.00$5.00M1,129,490
City Capital Llc Bay
10% owner
Oct 26, 2021Conversion+665,696––665,696
City Capital Llc Bay
10% owner
Oct 26, 2021Conversion+151,294––816,990
RiverVest Venture Fund IV, L.P.
10% owner
Oct 26, 2021Buy+250,000$16.00$4.00M1,441,444
RiverVest Venture Fund IV, L.P.
10% owner
Oct 26, 2021Conversion+832,120––832,120
RiverVest Venture Fund IV, L.P.
10% owner
Oct 26, 2021Conversion+359,324––1,191,444
Atlas Venture Opportunity Fund I, L.P.
10% owner
Oct 26, 2021Buy+187,500$16.00$3.00M735,942
Atlas Venture Opportunity Fund I, L.P.
10% owner
Oct 26, 2021Conversion+1,372,998––1,399,313
Atlas Venture Opportunity Fund I, L.P.
10% owner
Oct 26, 2021Conversion+624,089––2,023,402
Atlas Venture Opportunity Fund I, L.P.
10% owner
Oct 26, 2021Conversion+548,442––548,442
Alexandria Venture Investments, LLC
10% owner
Oct 26, 2021Conversion+166,423––166,423

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
6.62%
0M shares short
Days to cover
20.3
At 0M shares a day
Change since last report
-4.4%
From 0M shares
Short volume, 20 days
38.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Xilio Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,621 shares on Oct 1, 2026 over the last 90 days.

See a number that looks wrong?